A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent Resolute Onyx 2.0 mm Clinical Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Ischaemic heart disorders
- Focus Registrational; Therapeutic Use
- Sponsors Medtronic
- 28 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.
- 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.